These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28744010)

  • 1. The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.
    Zhan H; Lin CHS; Segal Y; Kaushansky K
    Leukemia; 2018 Feb; 32(2):462-469. PubMed ID: 28744010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2
    Lin CH; Kaushansky K; Zhan H
    Blood Cells Mol Dis; 2016 Nov; 62():42-48. PubMed ID: 27865175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling.
    Zhang Y; Lin CHS; Kaushansky K; Zhan H
    Stem Cells; 2018 Nov; 36(11):1676-1684. PubMed ID: 30005133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment.
    Mazzeo C; Quan M; Wong H; Castiglione M; Kaushansky K; Zhan H
    Blood Cells Mol Dis; 2021 Sep; 90():102585. PubMed ID: 34139651
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Lin CHS; Zhang Y; Kaushansky K; Zhan H
    Haematologica; 2018 Jul; 103(7):1160-1168. PubMed ID: 29567773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
    Kaushansky K; Zhan H
    Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
    Sangkhae V; Etheridge SL; Kaushansky K; Hitchcock IS
    Blood; 2014 Dec; 124(26):3956-63. PubMed ID: 25339357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
    Dunbar A; Nazir A; Levine R
    Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative Neoplasms.
    Zhang H; Kafeiti N; Masarik K; Lee S; Yang X; Zheng H; Zhan H
    Arterioscler Thromb Vasc Biol; 2024 Sep; 44(9):1960-1974. PubMed ID: 38989576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hematopoietic Microenvironment in Myeloproliferative Neoplasms: The Interplay Between Nature (Stem Cells) and Nurture (the Niche).
    Zhan H; Kaushansky K
    Adv Exp Med Biol; 2020; 1273():135-145. PubMed ID: 33119879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.
    Castiglione M; Jiang YP; Mazzeo C; Lee S; Chen JS; Kaushansky K; Yin W; Lin RZ; Zheng H; Zhan H
    J Thromb Haemost; 2020 Dec; 18(12):3359-3370. PubMed ID: 32920974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating CD133+/–CD34– Have Increased c-
    Uslu Bıçak İ; Tokcan B; Yavuz AS; Tokdemir SS
    Turk J Haematol; 2023 Feb; 40(1):28-36. PubMed ID: 36458557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2V617F Mutant Megakaryocytes Contribute to Hematopoietic Aging in a Murine Model of Myeloproliferative Neoplasm.
    Lee S; Wong H; Castiglione M; Murphy M; Kaushansky K; Zhan H
    Stem Cells; 2022 Apr; 40(4):359-370. PubMed ID: 35260895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2
    Zhan H; Ma Y; Lin CH; Kaushansky K
    Leukemia; 2016 Dec; 30(12):2332-2341. PubMed ID: 27133820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
    Sun T; Zhang L
    Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?
    Chen E; Mullally A
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):268-76. PubMed ID: 25696866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm.
    Zhang H; Yeware A; Lee S; Zhan H
    Front Oncol; 2021; 11():753465. PubMed ID: 34765558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional interdependence of hematopoietic stem cells and their niche in oncogene promotion of myeloproliferative neoplasms: the 159th biomedical version of "it takes two to tango".
    Zhan H; Kaushansky K
    Exp Hematol; 2019 Feb; 70():24-30. PubMed ID: 30593829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression.
    Klein C; Zwick A; Kissel S; Forster CU; Pfeifer D; Follo M; Illert AL; Decker S; Benkler T; Pahl H; Oostendorp RA; Aumann K; Duyster J; Dierks C
    J Exp Med; 2016 Feb; 213(2):273-90. PubMed ID: 26834157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.
    Yan D; Jobe F; Hutchison RE; Mohi G
    Leukemia; 2015 Oct; 29(10):2050-61. PubMed ID: 26044284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.